CoChat

Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment

Open access
Soukup, Ondrej, Winder, Michael, Killi, Uday Kumar, Wsol, Vladimir, Jun, Daniel, Kuca, Kamil, Tobin, Gunnar · 2017 · Current Neuropharmacology

The DOI matches its Crossref record; 240 of the 241 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

BACKGROUND: Pharmaceuticals with targets in the cholinergic transmission have been used for decades and are still fundamental treatments in many diseases and conditions today. Both the transmission and the effects of the somatomotoric and the parasympathetic nervous systems may be targeted by such treatments. Irrespective of the knowledge that the effects of neuronal signalling in the nervous systems may include a number of different receptor subtypes of both the nicotinic and the muscarinic receptors, this complexity is generally overlooked when assessing the mechanisms of action of pharmaceuticals. METHODS: We have search of bibliographic databases for peer-reviewed research literature focused on the cholinergic system. Also, we have taken advantage of our expertise in this field to deduce the conclusions of this study. RESULTS: Presently, the life cycle of acetylcholine, muscarinic receptors and their effects are reviewed in the major organ systems of the body. Neuronal and non-neuronal sources of acetylcholine are elucidated. Examples of pharmaceuticals, in particular cholinesterase inhibitors, affecting these systems are discussed. The review focuses on salivary glands, the respiratory tract and the lower urinary tract, since the complexity of the interplay of different muscarinic receptor subtypes is of significance for physiological, pharmacological and toxicological effects in these organs. CONCLUSION: Most pharmaceuticals targeting muscarinic receptors are employed at such large doses that no selectivity can be expected. However, some differences in the adverse effect profile of muscarinic antagonists may still be explained by the variation of expression of muscarinic receptor subtypes in different organs. However, a complex pattern of interactions between muscarinic receptor subtypes occurs and needs to be considered when searching for selective pharmaceuticals. In the development of new entities for the treatment of for instance pesticide intoxication, the muscarinic receptor selectivity needs to be considered. Reactivators generally have a muscarinic M2 receptor acting profile. Such a blockade may engrave the situation since it may enlarge the effect of the muscarinic M3 receptor effect. This may explain why respiratory arrest is the major cause for deaths by esterase blocking.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x14666160607212615

Cites

240 of 241 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) Schematic drawing of muscarinic receptor subtypes in the urinary bladder. The upper panel (a) indicates the filling phase of the urinary bladder. In this phase a limited amount of acetylcholine is released from neuronal (parasympathetic) and non-neuronal tissues (e.g. the urothelium). Adrenergic stimulation of relaxatory β3-adrenoceptors (by noradrenaline or adrenaline) is indicated. Relaxatory urothelial factors (e.g. nitric oxide released by activation of muscarinic receptors) stabilize the detrusor. Postsynaptic muscarinic M2 receptors inhibit the effects of contractile muscarinic M3 receptors. Presynaptic muscarinic M4 receptors inhibit the release of transmitter. The lower panel (b) indicates the emptying phase (detrusor contraction). In this phase a large number of vesicles release acetylcholine. Presynaptic muscarinic M1 receptors are activated and facilitate the release. The intense stimulation of contractile muscarinic M3 receptors overcomes any inhibitory effect of postsynaptic muscarinic M2 receptors. The muscarinic M2 receptors inhibit relaxatory effects via β3-adrenoceptors. Excitatory factors (e.g. ATP) are released from the urothelium. Both synaptic acetylcholinesterase and non-synaptic butyrylcholinesterase metabolizes acetylcholine.
Fig. (1) Schematic drawing of muscarinic receptor subtypes in the urinary bladder. The upper panel (a) indicates the filling phase of the urinary bladder. In this phase a limited amount of acetylcholine is released from neuronal (parasympathetic) and non-neuronal tissues (e.g. the urothelium). Adrenergic stimulation of relaxatory β3-adrenoceptors (by noradrenaline or adrenaline) is indicated. Relaxatory urothelial factors (e.g. nitric oxide released by activation of muscarinic receptors) stabilize the detrusor. Postsynaptic muscarinic M2 receptors inhibit the effects of contractile muscarinic M3 receptors. Presynaptic muscarinic M4 receptors inhibit the release of transmitter. The lower panel (b) indicates the emptying phase (detrusor contraction). In this phase a large number of vesicles release acetylcholine. Presynaptic muscarinic M1 receptors are activated and facilitate the release. The intense stimulation of contractile muscarinic M3 receptors overcomes any inhibitory effect of postsynaptic muscarinic M2 receptors. The muscarinic M2 receptors inhibit relaxatory effects via β3-adrenoceptors. Excitatory factors (e.g. ATP) are released from the urothelium. Both synaptic acetylcholinesterase and non-synaptic butyrylcholinesterase metabolizes acetylcholine.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 241 references

Research works printed but not linked: 2

  1. [93]Marrs T.C. Organophosphate poisoning. Pharmacol. Ther. 1993 58 1 51 66 [http://dx.doi.org/10.1016/0163-7258(93)90066-M]. [PMID: 8415873]. 8415873 · DOI · Paper page
  2. [143]Garcia-Carrasco M. Escarcega R.O. Fuentes-Alexandro S. Riebeling C. Cervera R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun. Rev. 2007 6 6 373 378 [http:// dx.doi.org/10.1016/j.autrev.2007.01.001]. [PMID: 17537383]. 17537383 · DOI

Cited by

See all 37

Metadata

Authors
Soukup, O., Winder, M., Killi, U. K., Wsol, V., Jun, D., Kuca, K., & Tobin, G.
Affiliations
  • University of Gothenburg (SE)
  • Charles University (CZ)
  • University Hospital Hradec Králové (CZ)
Corresponding author
Tobin, Gunnar
Venue
Current Neuropharmacology
Published
2017-04-11
Volume
15
Issue
4
Pages
637-653
ISSN
1570-159X (ISSN-L)
OpenAlex
W2413641555
Cited by
34
References
239
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 1 · 2017: 1
FWCI
0.21
Type
journal article
Language
en
Open access
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Fakultní nemocnice Hradec Králové (00179906)
  • European Regional Development Fund (ED2.1.00/03.0078)
  • National Institute of Mental Health (ED2.1.00/03., ED2.1.00/03.0078)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
acetylcholinesterase inhibitors, muscarinic receptors, muscarinic receptor subtypes, cholinergic neurotransmission, antimuscarinic agents, acetylcholine, salivary glands, respiratory tract, lower urinary tract, M2 muscarinic receptor, M3 muscarinic receptor, pesticide poisoning, adverse drug reactions, receptor selectivity
MeSH terms
Animals, Cholinesterase Inhibitors, Humans, Receptors, Muscarinic, Receptor Cross-Talk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. https://app.cochat.ai/papers/10.2174/1570159x14666160607212615
The paper
Soukup, O., Winder, M., Killi, U. K., Wsol, V., Jun, D., Kuca, K., & Tobin, G. (2017). Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. Current Neuropharmacology. https://doi.org/10.2174/1570159x14666160607212615

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.